Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases

17Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The recent derivation of disease-specific induced pluripotent stem cells (iPSCs) from somatic cells of patients with familial and sporadic forms of diseases and the demonstration of their ability to give rise to disease-relevant cell types provide an excellent opportunity to gain further insights into the mechanisms responsible for the pathophysiology of these diseases and develop novel therapeutic drugs. Here, we review the recent advances in iPSC technology for modeling of various lysosomal storage diseases (LSDs) and discuss possible strategies through which LSD-iPSCs can be exploited to identify novel drugs and improve future clinical treatment of LSDs. © 2012 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Huang, H. P., Chuang, C. Y., & Kuo, H. C. (2012). Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases. Stem Cell Research and Therapy. https://doi.org/10.1186/scrt125

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free